Nadeem Q. Mirza - May 1, 2024 Form 3 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Chief Medical Officer
Signature
/s/ John P. Hamill, Attorney-in-Fact
Stock symbol
APRE
Transactions as of
May 1, 2024
Transactions value $
$0
Form type
3
Date filed
5/2/2024, 04:15 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding APRE Stock Option (Right to Buy) May 1, 2024 Common Stock 2.25K $7.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the options vested on February 15, 2024, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued engagement with the Issuer through and including the applicable vesting dates and subject to acceleration under certain conditions. This option was granted to the Reporting Person while the Reporting Person was providing consulting services to the Issuer prior to his employment with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney